This analysis reports improved survival rates in metastatic pancreatic cancer using gemcitabine plus nab-paclitaxel, suggesting its effectiveness as a treatment option.
In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 5.6 to 7.1), and the median OS was 8.6 months (95% CI, 7.3 to 10.0)." now reads: "In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 4.6 to 6.0), and the median OS was 8.6 months (95% CI, 7.3 to 10.0)."
No takes yet. Share an insight, caveat, or question.
Sezgin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: